α-amino-α'-halomethylketones: Synthetic methodologies and pharmaceutical applications as serine and cysteine protease inhibitors

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 7, 2013, Pages 988-996

  Pace, Vittorio ^a,b   Castoldi, Laura ^a,c   Pregnolato, Massimo ^c  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Aminoketones; Drug synthesis; Haloketones; Inhibitors; Proteases; Structure activity relationship

Indexed keywords

ALPHA AMINO ALPHA HALOMETHYLKETONE; ALPHA CARBAMOYL ALKYLCARBONYL ASPARTYL FLUOROMETHYL KETONE; AMINOKETONE; AMPRENAVIR; CALPAIN 1; CYSTEINE PROTEINASE INHIBITOR; DIAZOMETHANE; FLUOROMETHYL KETONE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTERLEUKIN 1BETA CONVERTING ENZYME; KETONE DERIVATIVE; NELFINAVIR; ORGANOLITHIUM COMPOUND; SAQUINAVIR; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BIOTRANSFORMATION; BRAIN ISCHEMIA; CELL PROTECTION; DRUG HYDROLYSIS; DRUG OXIDATION; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROPHILICITY; HEART INFARCTION; HUMAN; HYDROPHOBICITY; IC 50; IMMUNE RESPONSE; PROTEIN DEGRADATION; STRUCTURE ACTIVITY RELATION; X RAY ANALYSIS;

EID: 84878636202     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557511313070004     Document Type: Article

References (69)

1. Reeder, M. R.; Anderson, R. M. α-Aminoalkyl-α-Halomethylketones: Preparation and Application to Pharmaceutically Interesting Compounds. Chem. Rev., 2006, 106, 2828-2842.
2. Concellón, J. M.; Rodríguez-Solla, H. Synthesis and synthetic applications of amino ketones derived from natural alphα-Amino acids. Curr. Org. Chem., 2008, 12, 524-543.
3. Baktharaman, S.; Hili, R.; Yudin, A. K. Amino Carbonyl Compounds in Organic Synthesis. Aldrichim. Acta, 2008, 41, 109-119.
4. De Kimpe, N.; Verhé, R., The Chemistry of α-Haloketones, α -Haloaldehydes and α-Haloimines. In The Chemistry of α-Haloketones, α-Haloaldehydes and α-Haloimines, Patai, S., Ed. Wiley: Chichester, 1988; pp 1-119.
5. Myers, A. G.; Barbay, J. K. On the Inherent Instability of α-Amino α'-Fluoro Ketones. Evidence for Their Transformation to Reactive Oxyvinyliminium Ion Intermediates. Org. Lett., 2001, 3, 425-428.
6. Pace, V.; Cortés-Cabrera, Á.; Fernández, M.; Sinisterra, J. V.; Alcántara, A. R. First General Route to Substituted a-chloropropan-2-ones by Oxidation of N-Protected Aminohalohydrins: The Importance of Disrupting Hydrogen Bond Networks. Synthesis, 2010, 3545-3555.
7. Hamada, T.; Torii, T.; Onishi, T.; Izawa, K.; Ikariya, T. Asymmetric Transfer Hydrogenation of α-Aminoalkyl αâ-Chloromethyl Ketones with Chiral Rh Complexes. J. Org. Chem., 2004, 69, 7391-7394.
8. Izawa, K.; Onishi, T. Industrial Syntheses of the Central Core Molecules of HIV Protease Inhibitors. Chem. Rev., 2006, 106, 2811-2827.
9. Pace, V.; Cortés-Cabrera, Á.; Ferrario, V.; Sinisterra, J. V.; Ebert, C; Gardossi, L.; Braiuca, P.; Alcántara, A. R. Structural bases for understanding the stereoselectivity in ketone reductions with ADH from Thermus thermophilus: A quantitative model. J. Mol. Catal. B: Enzym., 2011, 70, 23-31.
10. Ng, J. S.; Przybyla, C. A.; Liu, C; Yen, J. C; Muellner, F. W.; Weyker, C. L. A practical synthesis of an HIV protease inhibitor intermediate - diastereoselective epoxide formation from chiral [alpha]-aminoaldehydes. Tetrahedron, 1995, 51, 6397-6410.
11. Kaldor, S. W.; Kalish, V. J.; Davies, J. F.; Shetty, B. V.; Fritz, J. E.; Appelt, K.; Burgess, J. A.; Campanale, K. M.; Chirgadze, N. Y.; Clawson, D. K.; Dressman, B. A.; Hatch, S. D.; Khalil, D. A.; Kosa, M. B.; Lubbehusen, P. P.; Muesing, M. A.; Patick, A. K.; Reich, S. H.; Su, K. S.; Tatlock, J. H. Viracept (Nelfinavir Mesylate, AG1343): A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease. J. Med. Chem., 1997, 40, 3979-3985.
12. Patel, R. N.; Banerjee, A.; McNamee, C. G.; Brzozowski, D. B.; Szarka, L. J. Preparation of chiral synthon for HIV protease inhibitor: stereoselective microbial reduction of N-protected [alpha]-aminochloroketone. Tetrahedron: Asymmetry, 1997, 8, 2547-2552.
13. Kempf, D. J.; Sham, H. L.; Marsh, K. C; Flentge, C. A.; Betebenner, D.; Green, B. E.; McDonald, E.; Vasavanonda, S.; Saldivar, A.; Wideburg, N. E.; Kati, W. M.; Ruiz, L.; Zhao, C.; Fino, L.; Patterson, J.; Molla, A.; Plattner, J. J.; Norbeck, D. W. Discovery of Ritonavir, a Potent Inhibitor of HIV Protease with High Oral Bioavailability and Clinical Efficacy. J. Med. Chem., 1998, 41, 602-617.
14. Honda, Y.; Katayama, S.; Kojima, M.; Suzuki, T.; Kishibata, N.; Izawa, K. New approaches to the industrial synthesis of HIV protease inhibitors. Org. Biomol. Chem., 2004, 2, 2061-2070.
15. Pace, V.; Hoyos, P.; Sinisterra, J. V.; Alcántara, A. R.; Holzer, W. Highly Regioselective and Efficient Synthesis of Aminoepoxides by Ring Closure of Aminohalohydrins Mediated by KF-Celite. Synlett, 2011, 1831-1834.
16. Arndt, F.; Eistert, B. Ein Verfahren zur Überführung von Carbonsäuren in ihre höheren Homologen bzw. deren Derivate. Ber. Dtsch. Chem. Ges., 1935, 68, 200-208.
17. Regitz, M.; Maas, G. Diazo Compounds - Properties and Synthesis, Academic Press: Orlando, 1986.
18. Ye, T.; McKervey, M. A. Organic Synthesis with.alpha.-Diazo Carbonyl Compounds. Chem. Rev., 1994, 94, 1091-1160.
19. G. New Syntheses of Diazo Compounds. Angew. Chem. Int. Ed., 2009, 48, 8186-8195.
20. Proctor, L. D.; Warr, A. J. Development of a Continuous Process for the Industrial Generation of Diazomethane. Org. Proc. Res. Dev., 2002, 6, 884-892.
21. Pinho, V. D.; Burtoloso, A. C. B. Preparation of a,b-Unsaturated Diazoketones Employing a Horner-Wadsworth-Emmons Reagent. J. Org. Chem., 2011, 76, 289-292.
22. Pace, V.; Verniest, G.; Sinisterra, J. V.; Alcántara, A. R.; De Kimpe, N. Improved Arndt-Eistert Synthesis of a-Diazoketones Requiring Minimal Diazomethane in the Presence of Calcium Oxide as Acid Scavenger. J. Org. Chem., 2010, 75, 5760-5763.
23. Wang, D.; Schwinden, M. D.; Radesca, L.; Patel, B.; Kronenthal, D.; Huang, M.-H.; Nugent, W. A. One-Carbon Chain Extension of Esters to a-Chloroketones: A Safer Route without Diazomethane. J. Org. Chem., 2004, 69, 1629-1633.
24. Barluenga, J.; Baragana, B.; Alonso, A.; Concellon, J. M. The first direct preparation of chiral functionalised ketones and their synthetic uses. J. Chem. Soc., Chem. Commun., 1994, 969-970.
25. Barluenga, J.; Baragana, B.; Concellon, J. M. High Diastereoselective Synthesis of Threo or Erythro Aminoalkyl Epoxides from.alpha. Amino Acids. J. Org. Chem., 1995, 60, 6696-6699.
26. Barluenga, J.; Canteli, R.-M.; Flórez, J. Novel Cleavage of Propargylamines by Reaction with Organolithium Compounds. J. Org. Chem., 1996, 61, 3646-3649.
27. Barluenga, J.; Baragana, B.; Concellon, J. M. Preparation and Synthetic Applications of Enantiopure (2S,3S)- or (2R,3S)-2-Halomethyl-1,2-epoxyalkan-3-amines. J. Org. Chem., 1999, 64, 2843-2846. For an alternative approach based on the use of Weinreb amides as the electrophiles, see: Pace, V.; Holzer, W.; Verniest, G.; Alcántara, A. R.; De Kimpe, N. Adv. Synth. Catal. 2013, in press, DOI: 10.1002/adsc.201201043
28. Wu, G.; Huang, M. Organolithium Reagents in Pharmaceutical Asymmetric Processes. Chem. Rev., 2006, 106, 2596-2616.
29. Pace, V.; Castoldi, L.; Hoyos, P.; Sinisterra, J. V.; Pregnolato, M.; Sánchez-Montero, J. M. Highly regioselective control of 1,2-addition of organolithiums to a,b-unsaturated compounds promoted by lithium bromide in 2-methyltetrahydrofuran: a facile and eco-friendly access to allylic alcohols and amines. Tetrahedron, 2011, 67, 2670-2675.
30. Pace, V. 1,3-dichloroacetone. Synlett, 2010, 2825-2826.
31. Pace, V.; Martínez, F.; Fernández, M.; Sinisterra, J. V.; Alcántara, A. R. Effective Monoallylation of Anilines Catalyzed by Supported KF. Org. Lett., 2007, 9, 2661-2664.
32. Pace, V.; Sinisterra, J. V.; Alcántara, A. R. Celite-Supported Reagents in Organic Synthesis: An Overview. Curr. Org. Chem., 2010, 14, 2384-2408.
33. Pace, V.; Castoldi, L.; Holzer, W. Highly chemoselective synthesis of aryl allylic sulfoxides through calcium hypobromite oxidation of aryl allylic sulfides. Tetrahedron Lett., 2012, 53, 967-972.
34. Pace, V.; Martínez, F.; Fernández, M.; Sinisterra, J. V.; Alcántara, A. R. Highly Efficient Synthesis of New α-Arylamino- α'-chloropropan-2-ones via Oxidative Hydrolysis of Vinyl Chlorides Promoted by Calcium Hypochlorite. Adv. Synth. Cat., 2009, 351, 3199-3206.
35. Pace, V.; Holzer, W. A straightforward and general access to α-phthalimido- α'-substituted propan-2-ones. Tetrahedron Lett., 10.1016/j.tetlet. 2012, 1007-1045.
36. Powers, J. C; Asgian, J. L.; Ekici, Ö. D.; James, K. E. Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases. Chem. Rev., 2002, 102, 4639-4750.
37. Leung, D.; Abbenante, G.; Fairlie, D. P. Protease Inhibitors: Current Status and Future Prospects. J. Med. Chem., 2000, 43, 305-341.
38. Otto, H.-H.; Schirmeister, T. Cysteine Proteases and Their Inhibitors. Chem. Rev., 1997, 97, 133-172.
39. Wolfenden, R.; Snider, M. J. The Depth of Chemical Time and the Power of Enzymes as Catalysts. Acc. Chem. Res., 2001, 34, 938-945.
40. Schoellmann, G.; Shaw, E. Direct Evidence for the Presence of Histidine in the Active Center of Chymotrypsin*. Biochemistry, 1963, 2, 252-255.
41. Shaw, E.; Mares-Guia, M.; Cohen, W. Evidence for an Active-Center Histidine in Trypsin through Use of a Specific Reagent, 1-Chloro-3-tosylamido-7-amino-2-heptanone, the Chloromethyl Ketone Derived from Na-Tosyl-L-lysine*. Biochemistry, 1965, 4, 2219-2224.
42. Poulos, T. L.; Alden, R. A.; Freer, S. T.; Birktoft, J. J.; Kraut, J. Polypeptide halomethyl ketones bind to serine proteases as analogs of the tetrahedral intermediate. X-ray crystallographic comparison of lysine- and phenylalanine-polypeptide chloromethyl ketone-inhibited subtilisin. J. Biol. Chem., 1976, 251, 1097-1103.
43. Powers, J. C, Reaction of serine proteases with halomethyl ketones. In Methods Enzymol, William B. Jakoby, M. W., Ed. Academic Press: 1977, 46, pp 197-208.
44. Powers, J. C; Harper, J. W., Proteinase Inhibitors. Barrett, A. J.; Salvensen, G. Eds.; Elsevier: Amsterdam, 1985.
45. Powers, J. C; Tanaka, T.; Harper, J. W.; Minematsu, Y.; Barker, L.; Lincoln, D.; Crumley, K. V.; Fraki, J. E.; Schechter, N. M. Mammalian chymotrypsin-like enzymes. Comparative reactivities of rat mast cell proteases, human and dog skin chymases, and human cathepsin G with peptide 4-nitroanilide substrates and with peptide chloromethyl ketone and sulfonyl fluoride inhibitors. Biochemistry, 1985, 24, 2048-2058.
46. Yoshida, N.; Everitt, M. T.; Neurath, H.; Woodbury, R. G.; Powers, J. C. Substrate specificity of two chymotrypsin-like proteases from rat mast cells. Studies with peptide 4-nitroanilides and comparison with cathepsin G. Biochemistry, 1980, 19, 5799-5804.
47. Hayashi, Y.; Iijima, K.; Katada, J.; Kiso, Y. Structure-activity relationship studies of chloromethyl ketone derivatives for selective human chymase inhibitors. Bioorg. Med. Chem. Lett., 2000, 10, 199-201.
48. Jia, Z.; Hasnain, S.; Hirama, T.; Lee, X.; Mort, J. S.; To, R.; Huber, C. P. Crystal Structures of Recombinant Rat Cathepsin B and a Cathepsin B-Inhibitor Complex. J. Biol. Chem., 1995, 270, 5527-5533.
49. Drenth, J.; Kalk, K. H.; Swen, H. M. Binding of chloromethyl ketone substrate analogs to crystalline papain. Biochemistry, 1976, 15, 3731-3738.
50. Mittl, P. R. E.; Di Marco, S.; Krebs, J. F.; Bai, X.; Karanewsky, D. S.; Priestle, J. P.; Tomaselli, K. J.; Grütter, M. G. Structure of Recombinant Human CPP32 in Complex with the Tetrapeptide Acetyl-Asp-Val-Ala-Asp Fluoromethyl Ketone. J. Biol. Chem., 1997, 272, 6539-6547.
51. Rasnick, D. Synthesis of peptide fluoromethyl ketones and the inhibition of human cathepsin B. Anal. Biochem., 1985, 149, 461-465.
52. Ahmed, N. K.; martin, L. A.; Watts, L. M.; Palmer, J.; Thornburg, L.; Prior, J.; Esser, R. E. Peptidyl fluoromethyl ketones as inhibitors of cathepsin B: Implication for treatment of rheumatoid arthritis. Biochem. Pharmacol, 1992, 44, 1201-1207.
53. Sasaki, T.; Kikuchi, T.; Fukui, I.; Murachi, T. Inactivation of Calpain I and Calpain II by Specificity-Oriented Tripeptidyl Chloromethyl Ketones. J. Biochem., 1986, 99, 173-179.
54. Goll, D. E.; Thompson, V. F.; Li, H.; Wei, W.; Cong, J. The Calpain System. Physiol. Rev., 2003, 83, 731-801.
55. Storr, S. J.; Carragher, N. O.; Frame, M. C; Parr, T.; Martin, S. G. The calpain system and cancer. Nat. Rev. Cancer, 2011, 11, 364-374.
56. Chatterjee, S.; Josef, K.; Wells, G.; Iqbal, M.; Bihovsky, R.; Mallamo, J. P.; Ator, M. A.; Bozyczko-Coyne, D.; Mallya, S.; Senadhi, S.; Siman, R. Potent fluoromethyl ketone inhibitors of recombinant human calpain I. Bioorg. Med. Chem. Lett., 1996, 6, 1237-1240.
57. Talanian, R. V.; Brady, K. D.; Cryns, V. L. Caspases as Targets for Anti-Inflammatory and Anti-Apoptotic Drug Discovery. J. Med. Chem., 2000, 43, 3351-3371.
58. Thornberry, N. A. Caspases: key mediators of apoptosis. Chem. Biol, 1998, 5, R97-R103.
59. Denault, J.-B.; Salvesen, G. S. Caspases: Keys in the Ignition of Cell Death. Chem. Rev., 2002, 102, 4489-4500.
60. Blanchard, H.; Kodandapani, L.; Mittl, P. R. E.; Marco, S. D.; Krebs, J. F.; Wu, J. C; Tomaselli, K. J.; Grütter, M. G. The three-dimensional structure of caspase-8: an initiator enzyme in apoptosis. Structure, 1999, 7, 1125-1133.
61. Wang, Y.; Huang, J.-C; Zhou, Z.-L.; Yang, W.; Guastella, J.; Drewe, J.; Cai, S. X. Dipeptidyl aspartyl fluoromethylketones as potent caspase-3 inhibitors: SAR of the P2 amino acid. Bioorg. Med. Chem. Lett., 2004, 14, 1269-1272.
62. Cai, S. X.; Guan, L.; Jia, S.; Wang, Y.; Yang, W.; Tseng, B.; Drewe, J. Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: SAR of the N-protecting group. Bioorg. Med. Chem. Lett., 2004, 14, 5295-5300.
63. Wang, Y.; Guan, L.; Jia, S.; Tseng, B.; Drewe, J.; Cai, S. X. Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: peptidomimetic replacement of the P2 α-Amino acid by a a-hydroxy acid. Bioorg. Med. Chem. Lett., 2005, 15, 1379-1383.
64. Afantitis, A.; Melagraki, G.; Sarimveis, H.; Koutentis, P. A.; Markopoulos, J.; Igglessi-Markopoulou, O. A Novel QSAR Model for Evaluating and Predicting the Inhibition Activity of Dipeptidyl Aspartyl Fluoromethylketones. QSAR Comb. Sci., 2006, 25, 928-935.
65. Smith, R. A.; Copp, L. J.; Coles, P. J.; Pauls, H. W.; Robinson, V. J.; Spencer, R. W.; Heard, S. B.; Krantz, A. New inhibitors of cysteine proteinases. Peptidyl acyloxymethyl ketones and the quiescent nucleofuge strategy. J. Am. Chem. Soc, 1988, 110, 4429-4431.
66. Krantz, A.; Copp, L. J.; Coles, P. J.; Smith, R. A.; Heard, S. B. Peptidyl (acyloxy)methyl ketones and the quiescent affinity label concept: the departing group as a variable structural element in the design of inactivators of cysteine proteinases. Biochemistry, 1991, 30, 4678-4687.
67. Estrov, Z.; Black, R.; Sleath, P.; Harris, D.; Van, Q.; LaPushin, R.; Estey, E.; Talpaz, M. Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation. Blood, 1995, 86, 4594-4602.
68. Livingston, D. J. In vitro and in vivo studies of ICE inhibitors. J. Cell. Biochem., 1997, 64, 19-26.
69. Bialas, A.; Grembecka, J.; Krowarsch, D.; Otlewski, J.; Potempa, J.; Mucha, A. Exploring the Sn Binding Pockets in Gingipains by Newly Developed Inhibitors: Structure-Based Design, Chemistry, and Activity. J. Med. Chem., 2006, 49, 1744-1753.